PHI Board member Jan Richardsson recently divested 5 328 shares in the company.
“The reason for the sale is that I needed to balance an option loss linked to a previous employment”, comments Richardsson.
After the sale, Richardsson owns 38 634 shares in PHI, privately and via companies.
Currently, the HoloMonitor fluorescence unit is being prepared for its first users.
Strong sales growth for the 3rd consecutive quarter. Recent advancements in regenerative medicine create additional growth potential in clinical applications for the company.
The strategic shift of sales and marketing continues to prove itself. Despite being a “slow summer quarter”, sales during May – July surpassed sales during any previous quarter.
